Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Background: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods:...

Podrobná bibliografie
Hlavní autoři:	Katarina Mirjačić Martinović, Ana Vuletić, Nevena Tišma Miletić, Irina Besu Žižak, Jelena Milovanović, Suzana Matković, Vladimir Jurišić
Médium:	Článek
Jazyk:	English
Vydáno:	Elsevier 2023-12-01
Edice:	Translational Oncology
Témata:	Metastatic melanoma patients BRAF wild type Pembrolizumab Cytokines Monitoring Outcome predictors
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S1936523323001857

Podobné jednotky

Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
Autor: Hana Garaj, a další
Vydáno: (2024-01-01)

Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
Autor: Senar Ebinç, a další
Vydáno: (2023-09-01)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
Autor: Wu L, a další
Vydáno: (2021-02-01)

Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients
Autor: Katarina Mirjačić Martinović, a další
Vydáno: (2023-04-01)

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
Autor: Dugan MM, a další
Vydáno: (2024-07-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
Autor: Polsky David, a další
Vydáno: (2004-12-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
Autor: Francesca Consoli, a další
Vydáno: (2020-07-01)

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study
Autor: Jacek Calik, a další
Vydáno: (2024-01-01)

Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease
Autor: Xiang Dan, a další
Vydáno: (2024-04-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
Autor: I. V. SAMOILENKO, a další
Vydáno: (2017-06-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
Autor: Ernesto Rossi, a další
Vydáno: (2023-01-01)

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects
Autor: Lance Wollenberg, a další
Vydáno: (2023-10-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
Autor: Bartoušková Marie, a další
Vydáno: (2020-08-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
Autor: Justin C. Moser, a další
Vydáno: (2019-12-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
Autor: Yu. S. Shakh-Paronyants, a další
Vydáno: (2023-03-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Autor: Dahlia Fedele, a další
Vydáno: (2024-01-01)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
Autor: Saba S. Shaikh, a další
Vydáno: (2022-11-01)

Melanoma: BRAFi Rechallenge
Autor: Christoforos S. Kosmidis, a další
Vydáno: (2023-05-01)

Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals
Autor: Milena Cavic, a další
Vydáno: (2023-04-01)

MEK inhibitors for the treatment of NRAS mutant melanoma
Autor: Sarkisian S, a další
Vydáno: (2018-08-01)

The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome
Autor: Lazaro Hiram Betancourt, a další
Vydáno: (2021-07-01)

Current State of Target Treatment in BRAF Mutated Melanoma
Autor: Enrica Teresa Tanda, a další
Vydáno: (2020-07-01)

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report
Autor: Marco Ghezzi, a další
Vydáno: (2020-03-01)

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab
Autor: Rozala Arko, a další
Vydáno: (2022-07-01)

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations
Autor: Ahmed Temirak, a další
Vydáno: (2025-02-01)

p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration
Autor: Pinakin Pandya, a další
Vydáno: (2022-01-01)

Update on the treatment of BRAFmut metastatic melanoma and future perspectives
Autor: Peter Mohr, a další
Vydáno: (2025-03-01)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
Autor: Karam Khaddour, a další
Vydáno: (2021-06-01)

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study
Autor: Igor V. Samoylenko, a další
Vydáno: (2024-10-01)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
Autor: Adi Kartolo, a další
Vydáno: (2022-03-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
Autor: Simeng Zhang, a další
Vydáno: (2023-01-01)

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report
Autor: Clara So, a další
Vydáno: (2022-05-01)

Braf protein mutation and its significancy within patients with melanoma
Autor: Julia Kuchnicka, a další
Vydáno: (2022-08-01)

Treatment of Advanced Melanoma: Past, Present and Future
Autor: Taku Fujimura, a další
Vydáno: (2020-09-01)

Comparison of Two Rapid Assays for the Detection of <i>BRAF</i> V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes
Autor: Elodie Long-Mira, a další
Vydáno: (2022-03-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
Autor: Walid Shalata, a další
Vydáno: (2023-02-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
Autor: Nakul Dar, a další
Vydáno: (2023-08-01)

Tyrosine kinase inhibitors via nasogastric tube may resolve severe ileus secondary to melanoma: A case report
Autor: Lena Groennendijk, a další
Vydáno: (2022-06-01)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
Autor: Francesco Serra, a další
Vydáno: (2021-08-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
Autor: O. I. Kit, a další
Vydáno: (2016-06-01)